Redeye provides a first comment on the fourth quarter report and webinar, which had some significant new information. Verrica plans to have a topline readout from the phase II study in basal cell carcinoma in H2 2024, so this programme is ahead of schedule. A full readout from ATLAS-IT-05 was presented, with 1 partial response, 8 stable disease and 11 progressive disease patients, showing LTX-315 has an effect. However, Lytix will not include 20 more patients in an expansion cohort, instead focusing on ATLAS-IT-06 in the neoadjuvant setting.

https://www.redeye.se/research/987568/lytix-focus-on-neoadjuvant-melanoma?utm_source=finwire&utm_medium=RSS

Redeye